DUBLIN–(BUSINESS WIRE)–Research and Markets (researchandmarkets.com/research/3b0638/prostate_cancer) has announced the addition of GlobalData ‘s new report “Prostate Cancer – BRIC Drug Forecasts and Treatment Analysis to 2020″ to their offering.

“Prostate Cancer – BRIC Drug Forecasts and Treatment Analysis to 2020”

our pharmaceutical report, Prostate Cancer – Brazil, Russia, India and China (BRIC) Drug Forecasts and Treatment Analysis to 2020 is an essential source of information and analysis on the prostate cancer therapeutics market in the emerging BRIC countries. the report provides comprehensive information on prostate cancer, highlighting the treatment guidelines. it identifies and analyzes the key trends shaping and driving the prostate cancer therapeutics market in Brazil, Russia, India and China. it analyzes the treatment usage patterns in the BRIC prostate cancer therapeutics market. the report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. the report provides valuable insights into the pipeline products within the global prostate cancer sector. it quantifies the unmet need in the BRIC prostate cancer therapeutics market, highlighting the opportunity for future players.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by our team of industry experts.

the scope of the report includes:

the report will enhance your decision making capability. it will allow you to:

• Develop business strategies and perform superior market quantification analysis by – Understanding the trends shaping and driving the Japanese prostate cancer therapeutics market. – Understanding the treatment preferences of physicians according to disease state and across treatment flow. – Assessing market sizing, forecasts and quantified growth opportunities in the BRIC prostate cancer therapeutics market up to 2020. – Quantifying the patient population in the BRIC countries to better design product pricing and launch plans.
• Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by – Performing benchmarking analysis and growth opportunities against currently marketed products. – Identifying market entry points based on safety, efficacy and pricing parameters. – Assessing competitiveness of products in market by understanding the strength and weakness of the current competition.
• Develop and design your in-licensing and out-licensing strategies by – Taking a comprehensive look of at the disease pipeline and identifying the most promising paradigm shifting products. – Assessing the strength of pipeline based on first-in-class, me-too and generic products and their lifecycle management.
• Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.

Prostate Cancer – Brazil, Russia, India and China (BRIC) Drug Forecasts and Treatment Analysis to 2020 is an essential source of information and analysis on the prostate cancer therapeutics market in the emerging BRIC countries. the report provides comprehensive information on prostate cancer, highlighting the treatment guidelines. it identifies and analyzes the key trends shaping and driving the prostate cancer therapeutics market in Brazil, Russia, India and China. it analyzes the treatment usage patterns in the BRIC prostate cancer therapeutics market. the report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. the report provides valuable insights into the pipeline products within the global prostate cancer sector. it quantifies the unmet need in the BRIC prostate cancer therapeutics market, highlighting the opportunity for future players.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

the Prostate Cancer Therapeutics Market was Driven by the Growth in Patient Volume and Annual Cost of Hormone-refractory Prostate Cancer Therapy

the authors analysis finds that the prostate cancer therapeutics market in BRIC (Brazil, Russia, India and China) is attractive and is primarily driven by the growth in the hormone-refractory prostate cancer therapeutics market. the growth in the number of total patients receiving treatment and increase in the annual cost of hormone-refractory prostate cancer therapy is expected to offset the impact of generic erosion in hormone-dependent prostate cancer therapy. the patient volume was driven by growth in treatment usage patterns such as diseased population, treatment seeking population, diagnosis population and prescription population. the annual cost of prostate cancer therapy between 2001 and 2009 was driven by increased uptake of chemotherapy using Taxotere. Expected launch of new therapies such as Provenge (sipuleucel-T) and Jevtana (cabazitaxel) will further drive the annual cost of therapy.

Hormone therapy using combination of hormone therapies such as LHRH agonists and androgen receptor antagonists is a prominent treatment regime. Taxotere is the current standard of care for patients that stop responding to hormone therapy. the introduction of new therapies for metastatic prostate cancer is expected to expand the market further.

• 1 Overview
• 2 Disease Overview
• 3 Market Characterization
• 4 Competitor Assessment
• 5 Pipeline Assessment
• 6 Unmet need and Target Product Profile
• 7 Strategic Assessment
• 8 Company Profiles
• 9 M&A Analysis
• 10 Appendix

Companies Mentioned:

For more information visit researchandmarkets.com/research/3b0638/prostate_cancer.